College of Medical and Dental Sciences Realignment

college of mds realignment

We are embracing an exciting opportunity to establish ourselves as an outstanding, distinctive centre for Life Sciences research and education, further strengthening our global position in this field.

To support this the College of Medical and Dental Sciences (MDS) is undergoing an organisational realignment. We will be changing from our current academic structure of five Schools to eight Institutes as below (seven research Institutes and one institute of education) to allow for clear focus on our areas of research strength and teaching excellence:

  • Institute of Applied Health Research
  • Institute of Cancer and Genomic Sciences
  • Institute of Cardiovascular Sciences
  • Institute of Immunology and Immunotherapy
  • Institute of Inflammation and Ageing
  • Institute of Metabolism and Systems Research
  • Institute of Microbiology and Infection (joint with College of Life and Environmental Sciences (LES))
  • Institute of Clinical Sciences

The seven new Research Institutes are focused around our scientific strengths and are targeted to areas of major clinical significance.  They are academic units in identified areas of high-performing research excellence, each finding innovative solutions to address big issues and having an ambitious strategy and empowered leadership.

Drawing together outstanding researchers around coherent and highly collaborative themes, they will be responsible for working with colleagues from across the UoB campus to lead the further development and delivery of the institutional Life Sciences research strategy*, championing interdisciplinary collaboration across the University’s Colleges and in partnership with our local NHS Trusts. Each will support the translational research agenda and together will cover a range of research areas.  From basic science through to the practical application of treatments in the clinic, the research institutes will deliver real life impact, changing and saving the lives of patients.

New financial investment in co-location of our research institutes will ensure our academics have access to key facilities and resources, enabling greater collaboration and providing the tools to make important things happen. 

A diverse range of committed and high-performing Professional Services staff, managed through integrated College-wide teams, will continue to provide vital support to the academic activity of the College.

From October 2015 you will have access to our new Institute web pages. Please bear with us in while we make these important changes.

The New Research Institutes...

The Institute of Applied Health Research is focused in two broad areas: (i) primary care & population health research; (ii) healthcare evaluation & methodology, and there is expertise in the main community focused clinical disciplines: public health, primary care and occupational medicine, and methodological expertise in biostatistics, health economics, clinical trials, evidence synthesis, medical ethics and qualitative research. With internationally recognised clinical trials capacity and expertise the Institute provides an exceptional collaborative framework for developing and delivering translational outputs from the University of Birmingham’s wider research portfolio. 

The Institute of Cancer and Genomic Sciences represents our major academic strengths in fundamental cancer research, particularly around cell biology, haematology, genetics and genomics, and cancer clinical trials. The latter of these is driven through our Cancer Research UK (CRUK) Cancer Clinical Trials Unit, which is the national lead for paediatric cancer trials. Additional key infrastructure includes an Experimental Cancer Medicine Centre, and the success of academic Haematology has provided a model for the development of a Leukaemia and Lymphoma Research (LLR) funded Trials Acceleration Programme (TAP) via Birmingham that links research nurses in 13 UK leukaemia centres, part of our wider status as a national LLR Centre of Excellence. A key driver for our future development will be the award of the West Midlands Genomic Medicine Centre, the largest in the UK and linking all 18 regional NHS Trusts, with academic leadership based within this Institute. 

The Institute of Cardiovascular Sciences is a developing area of strength, focused around two key themes: Vascular Inflammation, Thrombosis & Angiogenesis; and Clinical & Integrative Cardiovascular Sciences. With a British Heart Foundation (BHF) Chair and a number of BHF senior Fellows, this is a highly collaborative cluster of activity, particularly championing interdisciplinary strengths through partnerships such as the Engineering and Physical Sciences Research Council (EPSRC) Physical Sciences for Health integrated Centre for Doctoral Training and the National Institute for Health Research (NIHR) Surgical Reconstruction & Microbiology Research Centre (SRMRC). 

The Institute of Immunology and Immunotherapy builds on the longstanding success of our MRC Centre for Immune Regulation in carrying out world-leading research into the fundamental mechanisms that regulate immune response, now driving translational outputs through closer integration with leading cancer immunology expertise. The NIHR  Biomedical Research Unit (BRU) in Liver Disease forms another key focus around which we are leading both nationally and internationally, with the establishment of our Advanced Therapies Facility providing state of the art cell and gene therapy suites with pharmacy facilities designed for gene, cell and biological therapies. Our Clinical Immunology Service supports a range of national cancer trials, and is the beneficiary of a recent £7.3M Medical Research Council (MRC) Clinical Infrastructure award to provide ‘deep’ phenotyping of patients involving immunological, metabolomic and DNA sequence analysis.

The Institute of Inflammation and Ageing benefits from a highly collaborative leadership team focused on translational outputs, based within a dedicated wing of the new Queen Elizabeth Hospital Birmingham (QEHB). The strength of their vision is represented by a number of major national awards, including the MRC-Arthritis Research UK (ARUK) Centre for Musculoskeletal Ageing (with Nottingham); ARUK Centre of Excellence in the Pathogenesis of RA (with Glasgow and Newcastle); ARUK Experimental Arthritis Treatment Centre; NIHR SRMRC; NIHR Healthcare Technology Cooperative (Trauma); and the Healing Foundation Burns Centre, as well as our key role in the NIHR Translational Research Partnership on Joint & Related Inflammatory Disease and NIHR SRMRC “Trauma” Centre along with collaborators in cardiovascular and microbiology research. 

The Institute of Metabolism and Systems Research is another rapidly developing area, drawing on longstanding strengths in endocrinology and reproductive health as well as metabolomics to create an integrated translational environment. As well as a key role in the MRC-ARUK Centre for Musculoskeletal Ageing Research, excellence in rare disease is recognised through our leadership of the UK paediatrics theme in the NIHR NOCRI Translational Research Collaboration ‘Rare Diseases’. The Institute also provides much of the academic drive for our NIHR-Wellcome Trust Clinical Research Facility, with facilities both at University Hospitals Birmingham and Birmingham Children’s Hospital, and recipient of the largest national NIHR award in the last round of funding. 

The Institute of Microbiology and Infection is a unique cross College Institute based in the Bioscience building. It draws together one of the largest national groupings of academic expertise in this area from researchers in LES and MDS, expert microbiologists, immunologists, biochemists and chemists, with technical expertise in next generation sequencing, genomics, proteomics, molecular and structural biology, biotechnology and modelling. Diverse research programmes encompass fundamental science of model organisms to the biochemical and biophysical analysis of microbial components to translational research on key pathogens of medical and veterinary importance. Major interests include pathogenomics, chromosome architecture and gene regulation, plasmids and mobile DNA, physiology and adaptive response, cell wall structure and membrane proteins, pathogenesis and host-pathogen interactions, infection and host-immune response, antibiotic and antimicrobial resistance and environmental biotechnology. 

While each of our Research Institutes will contribute to the delivery of outstanding teaching, our dedicated Institute of Clinical Sciences will provide the clear focus for integrating our education and training programmes, co-ordinating all teaching, student engagement and related activity across the College and including a number of operational and management sub-units. The Education Institute will deliver an improved, high quality student experience and be the home for our clinical professional Schools. 

The new structure will encourage inter-disciplinary and cross-College collaboration to address major health issues.

Contact

For any questions or queries over the new MDS structure, or the University Life Sciences Strategy, please email to lifesciencesstrategy@contacts.bham.ac.uk

*University of Birmingham Life Sciences Strategy

The Life Sciences Strategy (LSS) at Birmingham focuses specifically on areas relevant to human health including clinical and biomedical sciences and human biology.

Following a Life Sciences Review in 2014, implementation of the subsequent Life Sciences Strategy is now underway and aims to establish the University as an outstanding, distinctive centre for Life Sciences research and education.

The LSS vision is to increase our international standing and become a leading contributor to the successful delivery of the government’s vision for Life Sciences in the UK.

The LSS is focused on consolidating and building upon our research and teaching activities in this area across the whole campus.  It will help to deliver the region’s ambition for establishing Birmingham as the UK capital for the Life Sciences sector, and the national vision to improve healthcare, contribute to economic growth and make the UK the best place to invest in life sciences research.

Realignment of the College of Medical and Dental Sciences is one of the actions to support LSS delivery.